(lp0
S'Market: The Stemline Therapeutics Inc.  Receives Average Recommendation ... Petro Global News 24 - Jan 25, 2017 A number of research analysts have recently weighed in on the company. HC Wainwright set a $34.00 price target on Stemline Therapeutics and gave the company a buy rating in a research note on Sunday, January 8th. Jefferies Group LLC set a $23.00&nbsp;...'
p1
aS"Stemline Therapeutics Inc.  Soars 7.83% on April 17 Equities.com - 12 hours ago Stemline Therapeutics Inc.  had a good day on the market for Monday April 17 as shares jumped 7.83% to close at $8.95.Stemline Therapeutics'  &quot;Buy&quot; Rating Reaffirmed at HC Wainwright - The Cerbat GemStemline Therapeutics Inc  Rating Reiterated by Cowen and Company - BBNS"
p2
aS'Why Stemline Therapeutics Inc Stock Is Climbing Today Motley Fool - Jan 6, 2017 The biotech stock rollercoaster known as Stemline Therapeutics Inc  popped Friday morning with a 21.8% gain, and it was still up about 14.5% as of 11:44 a.m.Stemline Therapeutics Announces Positive FDA Meeting and Agreement on ... - GlobeNewswire Stemline Therapeutics  Spikes after announcing FDA Agreement - Economic Calendar'
p3
aS'Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results GlobeNewswire  - Mar 16, 2017 NEW YORK, March 16, 2017  -- Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today financial results&nbsp;...'
p4
aS'Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL ... GlobeNewswire  - Mar 23, 2017 NEW YORK, March 23, 2017  -- Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today that enrollment&nbsp;...'
p5
aS"Here's Why Stemline Therapeutics Stock Fell 36.9% This Morning Motley Fool - Feb 2, 2017 Shares of Stemline Therapeutics  tumbled nearly 37% this morning after investors learned that a patient died in a clinical trial involving its lead drug candidate, SL-401."
p6
aS'SHAREHOLDER ALERT: Faruqi &amp; Faruqi, LLP Reminds Investors In Stemline ... PR Newswire  - Mar 24, 2017 NEW YORK, March 23, 2017 /PRNewswire/ -- Faruqi &amp; Faruqi, LLP, a leading national securities law firm, reminds investors in Stemline Therapeutics, Inc.   of the April 4, 2017 deadline to seek the role of lead&nbsp;...'
p7
aS'Stemline Therapeutics Inc  Short Interest Up 43.3% in March The Cerbat Gem - Apr 17, 2017 Stemline Therapeutics logo Stemline Therapeutics Inc  was the target of a significant growth in short interest during the month of March.Is There Upside To Stemline Therapeutics, Inc.  Acorn Energy, Inc ... - Rives JournalStemline Therapeutics Inc  Receives &quot;Buy&quot; Rating from Cowen and Company - Sports Perspectives'
p8
aS"ALERT: Rosen Law Firm Reminds Stemline Therapeutics, Inc. Investors of ... Yahoo Finance - Mar 13, 2017 NEW YORK, March 13, 2017  -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Stemline Therapeutics, Inc. securities :  pursuant and/or traceable to Stemline's secondary public offering on or about&nbsp;..."
p9
aS"Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral ... GlobeNewswire  - Dec 5, 2016 NEW YORK, Dec. 05, 2016  -- Stemline Therapeutics, Inc.  announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic plasmacytoid dendritic&nbsp;..."
p10
a.